Literature DB >> 20051635

The therapeutic promise of the cancer stem cell concept.

Natasha Y Frank1, Tobias Schatton, Markus H Frank.   

Abstract

Cancer stem cells (CSCs) are a subpopulation of tumor cells that selectively possess tumor initiation and self-renewal capacity and the ability to give rise to bulk populations of nontumorigenic cancer cell progeny through differentiation. As we discuss here, they have been prospectively identified in several human malignancies, and their relative abundance in clinical cancer specimens has been correlated with malignant disease progression in human patients. Furthermore, recent findings suggest that clinical cancer progression driven by CSCs may contribute to the failure of existing therapies to consistently eradicate malignant tumors. Therefore, CSC-directed therapeutic approaches might represent translationally relevant strategies to improve clinical cancer therapy, in particular for those malignancies that are currently refractory to conventional anticancer agents directed predominantly at tumor bulk populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051635      PMCID: PMC2798700          DOI: 10.1172/JCI41004

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  124 in total

1.  Stemming the flood.

Authors:  Keith S Hoek; Ossia M Eichhoff; Daniel Widmer; Reinhard Dummer
Journal:  Pigment Cell Melanoma Res       Date:  2008-12-23       Impact factor: 4.693

Review 2.  Mesenchymal stem cells in health and disease.

Authors:  Antonio Uccelli; Lorenzo Moretta; Vito Pistoia
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

3.  ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome.

Authors:  Aaron M Elliott; Muhammad A Al-Hajj
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

4.  Crypt stem cells as the cells-of-origin of intestinal cancer.

Authors:  Nick Barker; Rachel A Ridgway; Johan H van Es; Marc van de Wetering; Harry Begthel; Maaike van den Born; Esther Danenberg; Alan R Clarke; Owen J Sansom; Hans Clevers
Journal:  Nature       Date:  2008-12-17       Impact factor: 49.962

5.  Identification of cancer stem cells in Ewing's sarcoma.

Authors:  Mario-Luca Suvà; Nicolò Riggi; Jean-Christophe Stehle; Karine Baumer; Stéphane Tercier; Jean-Marc Joseph; Domizio Suvà; Virginie Clément; Paolo Provero; Luisa Cironi; Maria-Chiara Osterheld; Louis Guillou; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

6.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

7.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  In vivo imaging, tracking, and targeting of cancer stem cells.

Authors:  Erina Vlashi; Kwanghee Kim; Chann Lagadec; Lorenza Della Donna; John Tyson McDonald; Mansoureh Eghbali; James W Sayre; Encrico Stefani; William McBride; Frank Pajonk
Journal:  J Natl Cancer Inst       Date:  2009-02-24       Impact factor: 13.506

9.  Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression.

Authors:  Charn-Jung Chang; Chuan-Chih Hsu; Ming-Chi Yung; Kai-Yun Chen; Ching Tzao; Wei-Fong Wu; Hsiang-Yun Chou; Yi-Yen Lee; Kai-Hsi Lu; Shih-Hwa Chiou; Hsin-I Ma
Journal:  Biochem Biophys Res Commun       Date:  2009-01-21       Impact factor: 3.575

10.  Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation.

Authors:  Liqin Zhu; Paul Gibson; D Spencer Currle; Yiai Tong; Robert J Richardson; Ildar T Bayazitov; Helen Poppleton; Stanislav Zakharenko; David W Ellison; Richard J Gilbertson
Journal:  Nature       Date:  2008-12-17       Impact factor: 49.962

View more
  278 in total

1.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors:  Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Hurdles in anticancer drug development from a regulatory perspective.

Authors:  Bertil Jonsson; Jonas Bergh
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

3.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

Review 4.  Drug rechallenge and treatment beyond progression--implications for drug resistance.

Authors:  Elizabeth A Kuczynski; Daniel J Sargent; Axel Grothey; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

5.  Comparison of Xiphophorus and human melanoma transcriptomes reveals conserved pathway interactions.

Authors:  Yuan Lu; Mikki Boswell; William Boswell; Susanne Kneitz; Michael Hausmann; Barbara Klotz; Janine Regneri; Markita Savage; Angel Amores; John Postlethwait; Wesley Warren; Manfred Schartl; Ronald Walter
Journal:  Pigment Cell Melanoma Res       Date:  2018-01-29       Impact factor: 4.693

6.  TNF-α induced epithelial mesenchymal transition increases stemness properties in renal cell carcinoma cells.

Authors:  Linlin Zhang; Min Jiao; Kaijie Wu; Lei Li; Guodong Zhu; Xinyang Wang; Dalin He; Dapeng Wu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

7.  HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.

Authors:  Kwon-Ho Song; Chel Hun Choi; Hyo-Jung Lee; Se Jin Oh; Seon Rang Woo; Soon-Oh Hong; Kyung Hee Noh; Hanbyoul Cho; Eun Joo Chung; Jae-Hoon Kim; Joon-Yong Chung; Stephen M Hewitt; Seungki Baek; Kyung-Mi Lee; Cassian Yee; Minjoo Son; Chih-Ping Mao; T C Wu; Tae Woo Kim
Journal:  Cancer Res       Date:  2017-07-17       Impact factor: 12.701

8.  Nanog signaling in cancer promotes stem-like phenotype and immune evasion.

Authors:  Kyung Hee Noh; Bo Wook Kim; Kwon-Ho Song; Hanbyoul Cho; Young-Ho Lee; Jin Hee Kim; Joon-Yong Chung; Jae-Hoon Kim; Stephen M Hewitt; Seung-Yong Seong; Chih-Ping Mao; T-C Wu; Tae Woo Kim
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

Review 9.  Obesity and cancer--mechanisms underlying tumour progression and recurrence.

Authors:  Jiyoung Park; Thomas S Morley; Min Kim; Deborah J Clegg; Philipp E Scherer
Journal:  Nat Rev Endocrinol       Date:  2014-06-17       Impact factor: 43.330

10.  ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit.

Authors:  Brian J Wilson; Karim R Saab; Jie Ma; Tobias Schatton; Pablo Pütz; Qian Zhan; George F Murphy; Martin Gasser; Ana Maria Waaga-Gasser; Natasha Y Frank; Markus H Frank
Journal:  Cancer Res       Date:  2014-06-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.